<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172974</url>
  </required_header>
  <id_info>
    <org_study_id>18/39431</org_study_id>
    <nct_id>NCT04172974</nct_id>
  </id_info>
  <brief_title>eHealth Intervention to Manage Depression and Anxiety in Patients With Ischemic Heart Disease</brief_title>
  <acronym>eMYHeart</acronym>
  <official_title>Screening and Managing Depression and Anxiety With Therapist-assisted eHealth Intervention in Patients With Ischemic Heart Disease in the Cardiac Rehabilitation Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense Patient Data Explorative Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effectiveness and cost-effectiveness of a therapy-assisted
      internet-based intervention in patients with ischemic heart disease and co-morbid depression
      and anxiety referred for cardiac rehabilitation. Half of the patients will receive the
      intervention and the other half usual care. We hypothesize that the intervention will lead to
      a reduction in patients' symptoms of depression and anxiety and be cost-effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 12-week intervention will consist of 9 modules and 2 optional modules that will be
      delivered to patients in the active intervention via a platform or app. Psychologists will
      provide asynchronous guidance via the platform. Motivational interviewing will be used during
      the intervention to prevent dropout. The psychologist may contact patients via telephone
      during the intervention if needed. All patients will have access to the intervention up to 6
      months' post intervention so that they can revisit the material and reuse it on a
      need-to-basis. Patients will be recommended to use this option and to note specific time
      points in their agenda where they will access the intervention. A brief purpose-designed
      interview protocol that includes elements from the SCAN interview will be carried out by
      psychologists trained in conducting the interview.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Comparison of depression/anxiety treatment versus usual care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms of depression</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by Hospital Anxiety and Depression Scale (range 0-21 - high score = more symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms of anxiety</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by Hospital Anxiety and Depression Scale (range 0-21 - high score = more symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of depression</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by Hospital Anxiety and Depression Scale (range 0-21 - high score = more symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of anxiety</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by Hospital Anxiety and Depression Scale (range 0-21 - high score = more symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of depression</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by Hospital Anxiety and Depression Scale (range 0-21 - high score = more symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of anxiety</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by Hospital Anxiety and Depression Scale (range 0-21 - high score = more symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by the Health-related quality of life questionnaire (HeartQoL) - The measure consists of a global, physical and emotional sub scale. Score range is from 0-3 (high score = better QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by the Health-related quality of life questionnaire (HeartQoL) - The measure consists of a global, physical and emotional sub scale. Score range is from 0-3 (high score = better QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by the Health-related quality of life questionnaire (HeartQoL) - The measure consists of a global, physical and emotional sub scale. Score range is from 0-3 (high score = better QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dropout</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients dropped out in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>3 months</time_frame>
    <description>EUROQOL - 5 Questions with 5 levels with level 5 being the worst level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>6 months</time_frame>
    <description>EUROQOL - 5 Questions with 5 levels with level 5 being the worst level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>12 months</time_frame>
    <description>EUROQOL - 5 Questions with 5 levels with level 5 being the worst level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress</measure>
    <time_frame>3 months</time_frame>
    <description>Measured with the Perceived Stress Scale (range 0-40 - high score = highest level of stress)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress</measure>
    <time_frame>6 months</time_frame>
    <description>Measured with the Perceived Stress Scale (range 0-40 - high score = highest level of stress)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress</measure>
    <time_frame>12 months</time_frame>
    <description>Measured with the Perceived Stress Scale (range 0-40 - high score = highest level of stress)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health complaints</measure>
    <time_frame>3 months</time_frame>
    <description>Measured with the Health Complaints Scale (range 0-95 - 95=worse health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health complaints</measure>
    <time_frame>6 months</time_frame>
    <description>Measured with the Health Complaints Scale (range 0-95 - 95=worse health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health complaints</measure>
    <time_frame>12 months</time_frame>
    <description>Measured with the Health Complaints Scale (range 0-95 - 95=worse health)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Depression, Anxiety</condition>
  <arm_group>
    <arm_group_label>Treatment for depression and anxiety</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Usual Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>eHealth intervention</intervention_name>
    <description>Modules developed for depression and anxiety based on cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT) and compassion-focused coping</description>
    <arm_group_label>Treatment for depression and anxiety</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Treatment according to national clinical guideline (referral to GP)</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Diagnosis of ischemic heart disease (diagnostic codes I20-I25)

          -  Referred for CR

          -  HADS score ≥ 8 on depression and or anxiety

          -  Access to a computer or smart phone

          -  Ability to use computer or smart phone

          -  Proficient in the Danish language

          -  Signing an informed consent form

        Exclusion Criteria:

          -  Severe psychiatric disorder (i.e., borderline disorder, schizophrenia or bipolar
             disorder)

          -  Severe cognitive difficulties (e.g. severe brain damage, mental retardation, or
             dementia) that will prevent patients from participating

          -  Endorsement of suicidal ideation with daily suicidal thoughts (PHQ-9 item 9 &gt;2)

          -  Participation in other intervention studies (unless they are clinical studies)

          -  Seeing a psychologist or mental health professional for the treatment of anxiety and
             depression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne S Pedersen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne S Pedersen, PhD</last_name>
    <phone>+4565507992</phone>
    <email>sspedersen@health.sdu.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leif Thuesen, MD</last_name>
      <email>leif.thuesen@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helle Lynge Kanstrup</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helle L Kanstrup, MD</last_name>
      <email>helle.kanstrup@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev / Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allan Z Iversen, MD</last_name>
      <email>allan.zeeberg.iversen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regionshospital Nordjylland</name>
      <address>
        <city>Hjørring</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gitte Nielsen, MD</last_name>
      <email>gn@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guldborgsund Municipality</name>
      <address>
        <city>Nykøbing Falster</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janet Lomholt</last_name>
      <email>jrl@guldborgsund.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital (Odense)</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susanne S Pedersen, PhD</last_name>
      <email>sspedersen@health.sdu.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten C Helmark</last_name>
      <email>kche@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital (Svendborg)</name>
      <address>
        <city>Svendborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Tveskov, MD</last_name>
      <email>claus.tveskov@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vordingborg Municipality</name>
      <address>
        <city>Vordingborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla B Henningsen</last_name>
      <email>ubhe@vordingborg.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

